✦ LIBER ✦

Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials

✍ Scribed by Hai T Tran; Yuan Liu; Amado J Zurita; Ying Lin; Katherine L Baker-Neblett; Anne-Marie Martin; Robert A Figlin; Thomas E Hutson; Cora N Sternberg; Rafael G Amado; Lini N Pandite; John V Heymach

Book ID: 119608921
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 623 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(12)70241-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Re: Prognostic or Predictive Plasma Cyto

Re: Prognostic or Predictive Plasma Cytokines and Angiogenic Factors for Patients Treated with Pazopanib for Metastatic Renal-cell Cancer: A Retrospective Analysis of Phase 2 and Phase 3 Trials

✍ Karam, Jose A.; Wood, Christopher G. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 41 KB

A cytokine and angiogenic factor (CAF) a

A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma

✍ Zurita, A. J.; Jonasch, E.; Wang, X.; Khajavi, M.; Yan, S.; Du, D. Z.; Xu, L.; H 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 586 KB

1404 POSTER DISCUSSION Baseline (BL) IL-

1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL)

✍ Y. Liu; H.T. Tran; Y. Lin; A.M. Martin; A. Zurita; C.N. Sternberg; V.E.G. Team; 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Overall survival in patients with metast

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

✍ Sergio Bracarda; Joaquim Bellmunt; Bohuslav Melichar; Sylvie Négrier; Emilio Baj 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB

Afatinib versus placebo for patients wit

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

✍ Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; San 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 373 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin